Literature DB >> 32462350

An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management.

Simona Toscano1, Salvatore Lo Fermo1, Ester Reggio1, Clara Grazia Chisari1, Francesco Patti1, Mario Zappia2.   

Abstract

Idiopathic intracranial hypertension is a neurological syndrome determined by a rise in intracranial pressure without a detectable cause. Course and prognosis may be changeable, requiring a multidisciplinary approach for its diagnosis and management. Although its precise pathogenesis is still unknown, many studies have been carried out to define the possible causal and associated factors, such as retinoids, steroid hormones, body mass index and recent weight gains, cytokines and adipokines levels. The clinical presentation can be variable including chronic headache, disturbance of vision, diplopia and tinnitus. Even if papilloedema is considered the most specific sign, it could not be observed in more than 5% of patients during the evaluation of the fundus oculi. Neuroradiological signs acquire greater importance in patients who do not present papilloedema and may suggest the diagnosis of idiopathic intracranial hypertension. Other assessments can be useful in the diagnostic process, such as optical coherence tomography, visual evoked potentials, ocular ultrasonography and fundus fluorescein angiography and autofluorescence. Nonetheless, cerebrospinal fluid pressure measurement is required to establish a definite diagnosis. Management may be different, since surgical procedures or lumbar punctures are often required when symptoms develop rapidly leading to a loss of visual function. Apart from these cases, patients can be treated with a pharmacological approach and low-calorie diet, but they also need to be monitored over time since relapses years later are not uncommon.

Entities:  

Keywords:  Acetazolamide; Idiopathic intracranial hypertension; Papilloedema; Pseudotumor cerebri; Transverse sinus stenosis

Year:  2020        PMID: 32462350     DOI: 10.1007/s00415-020-09943-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  7 in total

1.  Letter to the editors: comment on "Emerging themes in idiopathic intracranial hypertension".

Authors:  Simona Toscano; Mario Zappia
Journal:  J Neurol       Date:  2021-01-20       Impact factor: 4.849

2.  Effect of mannitol bolus administration on cerebrospinal fluid pressure in patients with idiopathic intracranial hypertension: a pilot study.

Authors:  Angelo Pascarella; Lucia Manzo; Francesco Bono
Journal:  J Neurol       Date:  2022-06-25       Impact factor: 6.682

3.  Dural Venous Sinus Stenosis: Why Distinguishing Intrinsic-versus-Extrinsic Stenosis Matters.

Authors:  S H Sundararajan; A D Ramos; V Kishore; M Michael; R Doustaly; F DeRusso; A Patsalides
Journal:  AJNR Am J Neuroradiol       Date:  2021-01-07       Impact factor: 3.825

4.  Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression.

Authors:  Ludger Tebartz van Elst; Dominique Endres; Maike Michel; Bernd L Fiebich; Hanna Kuzior; Sophie Meixensberger; Benjamin Berger; Simon Maier; Kathrin Nickel; Kimon Runge; Dominik Denzel; Benjamin Pankratz; Miriam A Schiele; Katharina Domschke
Journal:  Transl Psychiatry       Date:  2021-05-21       Impact factor: 6.222

5.  Pseudotumor Cerebri with Blindness.

Authors:  Myoung Kwak; Gerald T Delk; Trilok Stead; Latha Ganti
Journal:  Cureus       Date:  2021-02-07

6.  Intracranial hypertension and empty Sella from adrenal adenoma and excessive and prolonged steroid usage: a case report.

Authors:  Naiqian Zhao; Weixia Yang; Xiaoyan Li; Li Wang; Ying Feng
Journal:  BMC Endocr Disord       Date:  2022-01-15       Impact factor: 2.763

7.  Anatomic Variation of the Lateral Sinus in Patients With Idiopathic Intracranial Hypertension: Delineation With Black-Blood Contrast-Enhanced MRI.

Authors:  Yu Tian; Zhe Zhang; Jing Jing; Kehui Dong; Dapeng Mo; Yilong Wang
Journal:  Front Neurol       Date:  2021-11-25       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.